Intratumoral injection of IL-12-encoding mRNA targeted to CSFR1 and PD-L1 exerts potent anti-tumor effects without substantial systemic exposure

• Main Authors: Claudia Augusta Di Trani (Author), Assunta Cirella (Author), Leire Arrizabalaga (Author), Maite Alvarez (Author), Ángela Bella (Author), Myriam Fernandez-Sendin (Author), Joan Salvador Russo-Cabrera (Author), Celia Gomar (Author), Nuria Ardaiz (Author), Alvaro Teijeira (Author), Elixabet Bolaños (Author), José González-Gomariz (Author), Itziar Otano (Author), Fernando Aranda (Author), Belén Palencia (Author), Aina Segués (Author), Shuyu Huang (Author), Sander M.J. van Duijnhoven (Author), Andrea van Elsas (Author), Ignacio Melero (Author), Pedro Berraondo (Author)
• Format: Book
• Published: Elsevier, 2023-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

IL-12 is a potent cytokine for cancer immunotherapy. However, its systemic delivery as a recombinant protein has shown unacceptable toxicity in the clinic. Currently, the intratumoral injection of IL-12-encoding mRNA or DNA to avoid such side effects is being evaluated in clinical trials. In this st...